Tanni Fahmina, Akker Eleonora, Zaman Muhammad M, Figueroa Nilka, Tharian Biju, Hupart Kenneth H
J Am Osteopath Assoc. 2020 Jul 16. doi: 10.7556/jaoa.2020.091.
Early diagnosis of coronavirus disease 2019 (COVID-19) and patient isolation are important for both individual patient care and disease containment. The diagnosis is confirmed by testing for the presence of nasopharyngeal viral RNA with a polymerase chain reaction assay, which has limited availability, variable turnaround time, and a high false-negative rate. The authors report that a rapid laboratory test, the eosinophil count, readily obtained from a routine complete blood cell count (CBC), may provide actionable clinical information to aid in the early recognition of COVID-19 in patients, as well as provide prognostic information.
To investigate the diagnostic and prognostic value of eosinopenia in COVID-19-positive patients.
The eosinophil results of routine CBC from the first 50 admitted COVID-19-positive patients were compared with the eosinophil results of 50 patients with confirmed influenza infection at the time of presentation to the emergency department at Coney Island Hospital in Brooklyn, New York. The number of patients with 0 eosinophils on the day of presentation was also compared between the 2 groups. Furthermore, the eosinophil counts in the 50 COVID-19 patients were reviewed for the first 5 days of their hospital stay and before discharge, along with the outcome (deceased vs discharged), and trends in eosinophil data were compared based on the outcome.
On the day of presentation, 30 patients in the COVID-19 group (60%) and 8 patients in the influenza group (16%) had an eosinophil count of 0. An additional 14 patients in the COVID-19 group had 0 eosinophils during the following 2 days; the total number of patients in the COVID-19 group who had 0 eosinophils on admission or during the ensuing 2 days was 44 (88%). In addition, 18 of 21 deceased patients in the COVID-19 group (86%) who initially presented with eosinopenia remained eosinopenic compared with 13 of 26 survivors (50%).
The absence of an eosinophil count in a CBC can aid in early diagnosis of COVID-19. It may be a useful tool in deciding whether to promptly isolate a patient and initiate specific therapies while waiting for confirmatory test results. Persistent eosinopenia after admission correlated with high disease severity and low rates of recovery.
2019冠状病毒病(COVID-19)的早期诊断和患者隔离对于个体患者护理和疾病控制都很重要。通过聚合酶链反应检测鼻咽部病毒RNA的存在来确诊,该检测可用性有限、周转时间可变且假阴性率高。作者报告称,一种快速实验室检测——嗜酸性粒细胞计数,可从常规全血细胞计数(CBC)中轻松获得,可能会提供可采取行动的临床信息,以帮助早期识别患者中的COVID-19,并提供预后信息。
研究COVID-19阳性患者中嗜酸性粒细胞减少的诊断和预后价值。
将纽约布鲁克林科尼岛医院急诊科收治的首批50例COVID-19阳性患者的常规CBC嗜酸性粒细胞结果与50例确诊流感感染患者的嗜酸性粒细胞结果进行比较。还比较了两组患者就诊当天嗜酸性粒细胞计数为0的患者数量。此外,回顾了50例COVID-19患者住院的前5天和出院前的嗜酸性粒细胞计数,以及结局(死亡与出院),并根据结局比较嗜酸性粒细胞数据的趋势。
就诊当天,COVID-19组30例患者(60%)和流感组8例患者(16%)的嗜酸性粒细胞计数为0。COVID-19组另有14例患者在接下来的2天内嗜酸性粒细胞计数为0;COVID-19组入院时或随后2天内嗜酸性粒细胞计数为0的患者总数为44例(88%)。此外,COVID-19组最初表现为嗜酸性粒细胞减少的21例死亡患者中有18例(86%)仍为嗜酸性粒细胞减少,而26例幸存者中有13例(50%)。
CBC中无嗜酸性粒细胞计数有助于COVID-19的早期诊断。在等待确诊检测结果时,它可能是决定是否立即隔离患者并启动特定治疗的有用工具。入院后持续嗜酸性粒细胞减少与疾病严重程度高和康复率低相关。